SCHEDULE: Silexion Therapeutics Corp: Reporting Persons Hold 0% Shares

Reporting Persons Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC have disclosed beneficial ownership of 0% of Silexion Therapeutics Corp's ordinary shares as of June 30, 2026.

Summary

• The filing is an amendment to a Schedule 13G, indicating a change in beneficial ownership reporting.
• The reporting persons are Mitchell P. Kopin, Daniel B. Asher, and Intracoastal Capital LLC.
• As of June 30, 2026, the reporting persons collectively beneficially owned 0 Ordinary Shares of Silexion Therapeutics Corp.
• This ownership excludes shares issuable upon exercise of two warrants held by Intracoastal Capital LLC.
• The exercise of these warrants is contingent on stockholder approval and subject to a 9.99% beneficial ownership blocker provision.

Sentiment

Score: 2

Explanation: StockSavvy.ai views this filing as negative due to the reporting persons currently holding 0% of the company's shares and the exercisability of their warrants being contingent on stockholder approval and subject to blocker provisions.

Positives

• The reporting persons hold warrants that could potentially lead to future share ownership.
• The blocker provisions on warrants are designed to prevent excessive ownership concentration.

Negatives

• Currently, the reporting persons beneficially own 0% of the company's ordinary shares.
• The exercisability of significant potential shareholdings (71,420 shares if warrants were exercisable) is subject to stockholder approval.
• The warrants contain blocker provisions that limit exercise if beneficial ownership exceeds 9.99%.

Risks

• Failure to obtain stockholder approval for warrant exercise could prevent the reporting persons from acquiring shares.
• The 9.99% blocker provision may limit the reporting persons' ability to increase their stake even if they wish to.
• The company's reliance on stockholder approval for warrant exercise introduces uncertainty.

Future Outlook

The future shareholding of the reporting persons is contingent on stockholder approval for the exercise of their warrants and is subject to a 9.99% ownership blocker.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are typically made by passive investors who acquire more than 5% of a company's stock. The current filing, showing 0% ownership but with exercisable warrants, suggests a potential future stake that is currently in a preliminary or conditional stage.

Stakeholder Impact

• Shareholders: The potential exercise of warrants could lead to dilution if approved, but also represents a potential increase in the reporting persons' stake, which could influence future corporate actions.
• Reporting Persons: Their ability to gain a significant stake is dependent on external factors (stockholder approval) and internal limitations (blocker provisions).

Next Steps

• Silexion Therapeutics Corp's stockholders will need to approve the issuance of ordinary shares upon exercise of Intracoastal Warrant 1 and Intracoastal Warrant 2.
• The reporting persons may exercise their warrants if stockholder approval is obtained and the 9.99% blocker provision is not triggered.

Key Dates

Keywords

Schedule 13G, Beneficial Ownership, Warrants, Stockholder Approval, Intracoastal Capital LLC, Silexion Therapeutics Corp